Arthur Kuan, born on May 1, 1978, is the CEO and Chairman of CG Oncology. He has a strong background in business, with an MBA from Harvard Business School and previous roles at major investment firms, which helped shape his...
Arthur Kuan, born on May 1, 1978, is the CEO and Chairman of CG Oncology. He has a strong background in business, with an MBA from Harvard Business School and previous roles at major investment firms, which helped shape his strategic insight in the healthcare sector. He started CG Oncology in 2017 and has led the company through its initial public offering, focusing on innovative cancer treatment solutions. Notably, he has played a key role in establishing CG Oncology’s partnerships with Asian markets to expand their reach. Arthur’s leadership is reflected in his solid financial strategy that includes effective resource allocation and performance-oriented compensation philosophy for executives. In 2022, he earned a total compensation of $535,130, which included a performance-based bonus, indicating a strong alignment of his interests with company performance goals. Arthur's commitment to transparency and accountability is evident in his active involvement in corporate governance and his dedication to advancing cancer therapies on a global scale.